Hobbs D C
Am J Med. 1986 Nov 28;81(5B):22-8.
A large body of data is available regarding the relationship between demographic factors, particularly age, sex, and disease state, and the pharmacokinetics of piroxicam. Of additional interest is the relationship between piroxicam pharmacokinetics (particularly steady-state plasma levels) and adverse effects. Studies with piroxicam that are reviewed herein include studies on kinetics in renal impairment, single-dose studies, multiple-dose studies, and therapeutic drug monitoring studies. Although results were not always consistent, some studies suggested that plasma levels of piroxicam tend to be increased in elderly female patients. However, the increases were small and did not correlate with adverse events. These data suggest that there is no correlation between piroxicam plasma concentrations and adverse events.
关于人口统计学因素，尤其是年龄、性别和疾病状态与吡罗昔康药代动力学之间的关系，已有大量数据。吡罗昔康药代动力学（特别是稳态血浆水平）与不良反应之间的关系也格外引人关注。本文所综述的吡罗昔康研究包括肾功能损害时的动力学研究、单剂量研究、多剂量研究以及治疗药物监测研究。尽管结果并非总是一致，但一些研究表明，老年女性患者的吡罗昔康血浆水平往往会升高。然而，升高幅度较小，且与不良事件无关。这些数据表明，吡罗昔康血浆浓度与不良事件之间不存在相关性。
